中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
17期
10-14
,共5页
直肠肿瘤%放射疗法%新辅助化疗
直腸腫瘤%放射療法%新輔助化療
직장종류%방사요법%신보조화료
Rectal neoplasms%Radiotherapy%Neoadjuvant chemotherapy
目的 评价新辅助放化疗联合直肠癌根治术治疗中晚期直肠癌的临床疗效.方法 将51例中晚期直肠癌患者按随机数字表法分为治疗组和对照组,治疗组26例,术前给予三维适形放疗同步XELOX方案化疗2个周期,治疗结束后4～6周行直肠癌根治术.对照组25例,给予XELOX方案化疗2个周期后行直肠癌根治术.结果 治疗组客观有效率为84.6％(22/26),对照组为60.0％(15/25),两组比较差异有统计学意义(P=0.049).治疗组根治性切除率为96.2％(25/26),明显高于对照组的76.0％(19/25),差异有统计学意义(P=0.037).治疗组保肛率为61.5％(16/26),对照组为20.0％ (5/25),两组比较差异有统计学意义(P=0.003).治疗组病理完全缓解率为26.9％(7/26),明显高于对照组的4.0％(1/25),差异有统计学意义(P=0.024).治疗组1、2、3年生存率分别为88.0％ (22/25)、60.0％(15/25)、32.0％ (8/25),显著高于对照组的62.5％(15/24)、29.2％(7/24)、8.3％(2/24),差异有统计学意义(P=0.038、0.030、0.040).治疗组1、2、3年复发率分别为8.0％(2/25)、20.0％(5/25)、36.0％(9/25),显著低于对照组的33.3％(8/24)、50.0％ (12/24)、66.7％(16/24),差异有统计学意义(P=0.028、0.027、0.032).结论 新辅助放化疗联合直肠癌根治术可以提高手术切除率、保肛率,延长生存期,可作为治疗中晚期直肠癌的一种有效治疗方法.
目的 評價新輔助放化療聯閤直腸癌根治術治療中晚期直腸癌的臨床療效.方法 將51例中晚期直腸癌患者按隨機數字錶法分為治療組和對照組,治療組26例,術前給予三維適形放療同步XELOX方案化療2箇週期,治療結束後4～6週行直腸癌根治術.對照組25例,給予XELOX方案化療2箇週期後行直腸癌根治術.結果 治療組客觀有效率為84.6％(22/26),對照組為60.0％(15/25),兩組比較差異有統計學意義(P=0.049).治療組根治性切除率為96.2％(25/26),明顯高于對照組的76.0％(19/25),差異有統計學意義(P=0.037).治療組保肛率為61.5％(16/26),對照組為20.0％ (5/25),兩組比較差異有統計學意義(P=0.003).治療組病理完全緩解率為26.9％(7/26),明顯高于對照組的4.0％(1/25),差異有統計學意義(P=0.024).治療組1、2、3年生存率分彆為88.0％ (22/25)、60.0％(15/25)、32.0％ (8/25),顯著高于對照組的62.5％(15/24)、29.2％(7/24)、8.3％(2/24),差異有統計學意義(P=0.038、0.030、0.040).治療組1、2、3年複髮率分彆為8.0％(2/25)、20.0％(5/25)、36.0％(9/25),顯著低于對照組的33.3％(8/24)、50.0％ (12/24)、66.7％(16/24),差異有統計學意義(P=0.028、0.027、0.032).結論 新輔助放化療聯閤直腸癌根治術可以提高手術切除率、保肛率,延長生存期,可作為治療中晚期直腸癌的一種有效治療方法.
목적 평개신보조방화료연합직장암근치술치료중만기직장암적림상료효.방법 장51례중만기직장암환자안수궤수자표법분위치료조화대조조,치료조26례,술전급여삼유괄형방료동보XELOX방안화료2개주기,치료결속후4～6주행직장암근치술.대조조25례,급여XELOX방안화료2개주기후행직장암근치술.결과 치료조객관유효솔위84.6％(22/26),대조조위60.0％(15/25),량조비교차이유통계학의의(P=0.049).치료조근치성절제솔위96.2％(25/26),명현고우대조조적76.0％(19/25),차이유통계학의의(P=0.037).치료조보항솔위61.5％(16/26),대조조위20.0％ (5/25),량조비교차이유통계학의의(P=0.003).치료조병리완전완해솔위26.9％(7/26),명현고우대조조적4.0％(1/25),차이유통계학의의(P=0.024).치료조1、2、3년생존솔분별위88.0％ (22/25)、60.0％(15/25)、32.0％ (8/25),현저고우대조조적62.5％(15/24)、29.2％(7/24)、8.3％(2/24),차이유통계학의의(P=0.038、0.030、0.040).치료조1、2、3년복발솔분별위8.0％(2/25)、20.0％(5/25)、36.0％(9/25),현저저우대조조적33.3％(8/24)、50.0％ (12/24)、66.7％(16/24),차이유통계학의의(P=0.028、0.027、0.032).결론 신보조방화료연합직장암근치술가이제고수술절제솔、보항솔,연장생존기,가작위치료중만기직장암적일충유효치료방법.
Objective To evaluate the clinical efficacy of neoadjuvant chemo radiotherapy combined with surgical treatment for advanced rectal cancer.Methods Fifty-one patients with advanced rectal cancer were randomly divided into treatment group and control group by random number table.In treatment group,26 cases received three-dimensional conformal radiotherapy synchronization XELOX chemotherapy for 2 cycles,then they received radical resection after 4-6 weeks.Twenty-five cases in control group received neoadjuvant chemotherapy with XELOX for 2 cycles,then received radical resection.Results The objective response rate in treatment group was 84.6％ (22/26),and in control group was 60.0％(15/25),there was significant difference between two groups (P =0.049).Radical resection in treatment group was 96.2％ (25/26),significantly higher than that in control group 76.0％ (19/25)(P =0.037).The sphincter preservation rate in treatment group was 61.5％ (16/26),and in control group was 20.0％ (5/25),there was significant difference between two groups (P =0.003).The pathologic complete response rate in treatment group was 26.9％ (7/26),significantly higher than that in control group 4.0％ (1/25)(P =0.024).The 1,2 and 3 year survival rate in treatment group were 88.0％(22/25),60.0％(15/25),32.0％(8/25),which were significantly higher than those in control group 62.5％ (15/24),29.2％ (7/24),8.3％ (2/24) (P =0.038,0.030,0.040).The 1,2,and 3 year recurrence rate in treatment group were 8.0％(2/25),20.0％(5/25),36.0％ (9/25),which were significantly lower than those in control group 33.3％ (8/24),44.8％(12/24),66.7％ (16/24) (P=0.028,0.027,0.032).Conclusion Neoadjuvant chemoradiotherapy can improve the rate of surgical resection,sphincter preservation and prolong survival of rectal cancer,it can be used as a kind of effective treatment for rectal cancer.
